{"analyses":[{"ciLowerLimit":"0.256","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.684","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0004","paramType":"Hazard Ratio (HR)","paramValue":"0.418","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% Confidence Interval unavailable due to high censoring.","groupId":"OG000","lowerLimit":"17.94","upperLimit":"NA","value":"24.18"},{"groupId":"OG001","lowerLimit":"9.69","upperLimit":"23.26","value":"11.99"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"64"}],"units":"Participants"}],"description":"DoR was defined as the time from the date that measurement criteria for CR or PR (whichever is first recorded) were first met until the first date that disease was recurrent or documented disease progression was observed, or the date of death from any cause in the absence of documented disease progression or recurrence. The DOR according to both BICR and investigator-assessed BOR was evaluated per RECIST 1.1 criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"160 mg Selpercatinib administered orally BID continuously in 21-day cycles.","id":"OG000","title":"Selpercatinib (TRT A)"},{"description":"Pemetrexed 500 mg/m2, IV on Day 1 Q3W plus investigator's choice of carboplatin AUC 5 (maximum dose 750 mg) IV or cisplatin 75mg/m2, IV on Day 1 Q3W for 4 cycles, plus investigator's choice with or without 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.","id":"OG001","title":"Pemetrexed and Platinum With or Without Pembrolizumab (TRT B)"}],"paramType":"MEDIAN","populationDescription":"ITT Population: All randomized participants, even if a participant did not take the assigned treatment, did not receive the correct treatment, or otherwise did not follow the protocol. Participants were analyzed according to the treatment arm they were assigned to regardless of what actual treatment they received. Participants censored: TRT A: 90; TRT B: 33.","reportingStatus":"POSTED","timeFrame":"Date of CR or PR to Date of Disease Progression or Death Due to Any Cause Up to 31 Months","title":"DOR by BICR (With or Without Pembrolizumab)","type":"SECONDARY","unitOfMeasure":"Months"}